Autoimmune Disease: When a virus lies in wait
A mouse model supports the hypothesis that latent Epstein–Barr virus exacerbates the symptoms of rheumatoid arthritis.
- The Shmunis School of Biomedicine and Cancer Research, the George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel
The body’s ability to fight a wide range of external (e.g. viruses, bacteria) and internal (e.g. cancer cells) threats relies on having a fully functional immune system. The immune system can be roughly divided into two parts: the innate system, which is activated quickly and considered the first line of defense; and the adaptive system, which usually ‘kicks in’ a few days following the initial infection and evolves over time to generate a long-lasting and specific response (Murphy et al., 2017).
The power of the adaptive immune system stems from the ability of its white blood cells – T cells and B cells – to express a diverse set of immune receptors that can bind to specific pathogens (Rubelt et al., 2017). As well as having receptors bound to their surface, B cells also secrete some of their receptors in the form of antibodies.
Some B cells, however, produce ‘autoantibodies’ that recognize and bind to molecules on the body’s own cells, causing the immune system to mistakenly attack normal, healthy tissue (Sogkas et al., 2021). There are many mechanisms in place to eliminate these B cells, but if they fail autoimmune disorders can arise (Theofilopoulos et al., 2017). Autoimmune diseases, such as systemic lupus erythematosus multiple sclerosis and rheumatoid arthritis, are thought to be triggered by past viral infections (McClain et al., 2005; Mameli et al., 2012; Costenbader and Karlson, 2006). For example, rheumatoid arthritis (RA) – an inflammatory autoimmune disease that affects the joints – has been associated with Epstein-Barr virus (EBV) infection (Guo et al., 2018; Costenbader and Karlson, 2006).
Most exposures to EBV occur during childhood or adolescence without leading to RA, but the disease tends to appear after patients turn 60. Thus, it is hypothesized that EBV latency – a situation in which the virus becomes dormant within the host cell without producing more viruses – may contribute to RA symptoms appearing later in life. This is in agreement with a previous study in which mice with an autoimmune condition called experimental autoimmune encephalopathy were latently infected with a homolog of EBV called gammaherpesvirus 68 (γHV68). The infection exacerbated the autoimmune condition without changing autoantibody levels, and led to a disease that resembles multiple sclerosis (Casiraghi et al., 2012). But it is unclear whether EBV has the same effect on RA.
Now, in eLife, Marc Horwitz and colleagues from the University of British Columbia – including Isobel Mouat as first author – report that latent viral infection also worsens the symptoms of a mouse model for RA (Mouat et al., 2021). They used a mouse model for RA that suffers from an autoimmune condition called type II collagen-induced arthritis (CIA). When these mice are exposed to type II collagen, they develop arthritis with a sustained T cell response and as a result produce anti-collagen autoantibodies that can infiltrate the joints (Inglis et al., 2007).
Mouat et al. infected CIA mice with latent γHV68 to develop a mouse model that can shed light on how EBV may affect the symptoms of RA in humans. The experiments showed that infection increased the clinical parameters used to measure the severity of CIA (Figure 1), demonstrating the negative impact of the latent virus. Specifically, a subset of B cells called age-associated B cells were shown to be expressed in significantly higher proportions than in uninfected mice. Finally, Mouat et al. used a strain of γHV68 that cannot become latent to show that latency is necessary for the virus to exacerbate CIA.
Figure 1
Parameters measured to determine CIA severity.
Top: Mice were infected with latent γHV68 and treated with type II collagen to model the effects of Epstein-Barr virus on rheumatoid arthritis. This manipulation causes the symptoms of type II collagen arthritis (CIA) to become more severe and increase inflammation in the mice’s joints. Bottom: the parameters measured to assess the severity of the autoimmune disease include (circle, clockwise from top left): the levels of the cytokine IFNγ in the spleen (which increased in the CIA mice infected with γHV68); the proportions of different T cell populations (which became similar to what is observed during infections); the phenotypes of B cells in the spleen (more age-associated B cells were observed); and the time until onset of the disease (which decreased). Created with BioRender.com.
Mouat et al. show that latent γHV68 infection in mice clearly alters autoimmune disease onset and severity, potentially reflecting how latent EBV infection affects RA in humans. Future research will be needed to reveal exactly how B cells are impacted by EBV. Notably, the development and validation of the RA model in mice will facilitate future studies aiming to better understand the nature of the relationship between EBV infection and RA.
References
-
Epstein-Barr virus and rheumatoid arthritis: is there a link?Arthritis Research & Therapy 8:204.https://doi.org/10.1186/ar1893
-
Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunityCellular & Molecular Immunology 18:1122–1140.https://doi.org/10.1038/s41423-020-00626-z
Article and author information
Author details
Publication history
Copyright
© 2021, Taussig and Wine
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 9,804
- views
-
- 185
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Autoimmune Disease: When a virus lies in wait
eLife 10:e71121.
https://doi.org/10.7554/eLife.71121
Further reading
-
- Immunology and Inflammation
The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasing worldwide. Since gut-derived bacterial lipopolysaccharides (LPS) can travel via the portal vein to the liver and play an important role in producing hepatic pathology, it seemed possible that (1) LPS stimulates hepatic cells to accumulate lipid, and (2) inactivating LPS can be preventive. Acyloxyacyl hydrolase (AOAH), the eukaryotic lipase that inactivates LPS and oxidized phospholipids, is produced in the intestine, liver, and other organs. We fed mice either normal chow or a high-fat diet for 28 weeks and found that Aoah-/- mice accumulated more hepatic lipid than did Aoah+/+ mice. In young mice, before increased hepatic fat accumulation was observed, Aoah-/- mouse livers increased their abundance of sterol regulatory element-binding protein 1, and the expression of its target genes that promote fatty acid synthesis. Aoah-/- mice also increased hepatic expression of Cd36 and Fabp3, which mediate fatty acid uptake, and decreased expression of fatty acid-oxidation-related genes Acot2 and Ppara. Our results provide evidence that increasing AOAH abundance in the gut, bloodstream, and/or liver may be an effective strategy for preventing or treating MASLD.
-
- Immunology and Inflammation
- Microbiology and Infectious Disease
Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.
